Sino Biopharmaceutical (HKG:1177) said unit LaNova Medicines's LM-302 has been included in the breakthrough therapeutic designation process by China's National Medical Products Administration, a late Tuesday Hong Kong bourse filing said.
Shares of the biopharmaceutical firm were up 1% in Wednesday afternoon trading.
The drug is used in combination with a PD-1 monoclonal antibody as first-line therapy for gastric and gastroesophageal junction adenocarcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.